Pfizer’s been trying for years to prove that its cholesterol-fighter Lipitor is better than Merck’s competitor Zocor — with mixed results. Today, Pfizer-sponsored researchers are at it again, presenting this poster at a big European cardiology conference that says patients who switched from Lipitor to Zocor had a higher risk of death or serious cardiovascular problems than those who continued taking Lipitor.
The Statin Switcheroo: Lipitor and Simvastatin
clipped from blogs.wsj.com
No comments:
Post a Comment